PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
Ralph Zinner(The University of Texas MD Anderson Cancer Center), Coleman K. Obasaju(University of Georgia), David R. Spigel(Eli Lilly (United States)), Robert Weaver(Washington University in St. Louis), J. Thaddeus Beck(Global Strategic Solutions (United States)), David Waterhouse(Global Strategic Solutions (United States)), Manuel Modiano(Arizona Oncology), Borys Hrinczenko(Michigan State University), Petros Nikolinakos(University of Georgia), Jingyi Liu(Eli Lilly (United States)), Andrew Koustenis(Eli Lilly (United States)), Katherine B. Winfree(University of Georgia), Symantha Melemed(Eli Lilly (United States)), Susan C. Guba(Eli Lilly (United States)), Waldo Ortuzar(Eli Lilly (United States)), D. Desaiah(Eli Lilly (United States)), Joseph Treat(Eli Lilly (United States)), Ramaswamy Govindan(Washington University in St. Louis), Helen J. Ross(Washington University in St. Louis)
Cited by 172Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis